Multiple Cancer-Associated Antigens Panel (MCAP)

This entry describes a panel of cancer-associated proteins, including prominent cancer-testis antigens (NY-ESO-1, MAGE-C1, MAGE-C2) and tumor-associated antigens (Survivin, 5T4, MUC1). These molecules are characterized by their robust expression in a wide range of solid and hematological malignancies, while typically being restricted or expressed at very low levels in most normal adult somatic tissues. This differential expression makes them highly attractive targets for cancer immunotherapy. Their biological functions vary, encompassing roles in cell cycle regulation, apoptosis, cell proliferation, cell adhesion, migration, and immune modulation, collectively contributing to tumor progression, survival, and immune evasion. Individually and as a panel, these antigens serve as crucial biomarkers for cancer diagnosis, prognosis, and therapeutic stratification, and are actively investigated as therapeutic targets for various immunotherapeutic approaches, including cancer vaccines (e.g., mRNA-based), engineered T cell therapies (CAR-T, TCR), and antibody-drug conjugates. Therapies aim to induce immune recognition and subsequent elimination of tumor cells expressing these antigens. Key challenges in their clinical development include addressing antigen heterogeneity within tumors, mitigating potential antigen loss leading to therapeutic resistance, and managing possible off-target immune responses due to low-level expression in certain normal tissues.

Other names

NY-ESO-1Cancer-testis antigen 1B (CTAG1B)NY-ESO-1 antigenMAGE-C1Cancer-testis antigen 7 (CT7)MAGE-C2Cancer-testis antigen 10 (CT10)SurvivinBIRC5Apoptosis inhibitor survivin5T4Oncofetal antigen 5T4MUC1Epithelial mucinCD227Cancer-testis antigensTumor-associated antigens

Drugs and vaccines targeting these antigens induce immune recognition and elimination/destruction of antigen-expressing tumor cells by activated cytotoxic T lymphocytes or engineered T cells. This involves vaccine-induced adaptive immunity and/or direct immune targeting. Inhibition of specific antigen functions (e.g., apoptosis inhibition for Survivin) can also lead to apoptosis and reduced cell proliferation. Antibodies and vaccines may target aberrantly glycosylated or overexpressed antigens on tumor cells, inducing immune-mediated cytotoxicity.